m8 Pharmaceutical Overview
- Founded
- 2007

- Status
- Private
- Employees
- 199

- Latest Deal Type
- Mezzanine
- Latest Deal Amount
- $25M

- Investors
- 6
m8 Pharmaceutical General Information
Description
Provider of specialty pharmaceutical services intended to focus on the commercialization of innovative and established therapeutics in Latin American markets. The company's services are provided by partnering with pharmaceutical companies looking to establish, maintain or expand their business presence in the Latin American market due to their understanding of the regulatory complexities, stringent quality assurance and adherence to international standards, enabling people to get high-value innovative and proven therapies across Latin America.
Contact Information
- 1055 Westlakes Drive
- Suite 300
- Berwyn, PA 19312
- United States
m8 Pharmaceutical Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
10. Mezzanine | 15-Feb-2019 | $25M | 00000 | Completed | Generating Revenue | |
9. Later Stage VC | 06-Jan-2014 | 00000 | Cancelled | Generating Revenue | ||
8. Secondary Transaction - Private | 22-Oct-2012 | 000.00 | 00000 | Completed | Generating Revenue | |
7. Early Stage VC | 14-Oct-2010 | 0000 | 00000 | 00000 | Completed | Startup |
6. Early Stage VC | 10-Jun-2010 | 00.00 | 000.00 | Completed | Startup | |
5. Early Stage VC | 01-Dec-2009 | 000.00 | 000.00 | 000.00 | Completed | Startup |
4. Early Stage VC | 05-Nov-2009 | 000 | 000.00 | Completed | Startup | |
3. Early Stage VC | 11-Feb-2009 | 00.000 | 000.00 | Completed | Startup | |
2. Early Stage VC (Series B) | 30-Jan-2008 | $15M | $39M | Completed | Startup | |
1. Early Stage VC (Series A) | 30-Jan-2008 | $24M | $24M | Completed | Startup |
m8 Pharmaceutical Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series 3a | 00,000,000 | 00.000000 | 0.00 | 00.0 | 00.0 | 00.0 | 00.000 | |
Series 3a | 00,000,000 | 00.000000 | 0.00 | 00.00 | 00.00 | 00.00 | 0.000 | |
Series 2 | 00,000,000 | 00.000000 | 0.00 | 00.00 | 00.00 | 00.00 | 00.000 | |
Series 1a | 1,858,968 | $0.001000 | 9.5% | $3.29 | $3.29 | $3.29 | 1.25% | |
Series 1 | 18,706,466 | $0.001000 | 9.5% | $0.9 | $0.9 | $0.9 | 12.59% |
m8 Pharmaceutical Executive Team (15)
m8 Pharmaceutical Board Members (13)
Name | Representing | Role | Since |
---|---|---|---|
Arthur Higgins | Self | Board Member | 000 0000 |
Daniel Turner III | Montreux Equity Partners | Board Member | 000 0000 |
Joel Barlan | m8 Pharmaceutical | Chief Executive Officer & Board Member | 000 0000 |
Mariano García-Valiño | m8 Pharmaceutical | Board Member | 000 0000 |
Pascal Forget | m8 Pharmaceutical | Board Member | 000 0000 |
m8 Pharmaceutical Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialm8 Pharmaceutical Investors (6)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Knight Therapeutics | Corporation | Minority | 000 0000 | 000000 0 | |
Votorantim New Business | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
Montreux Equity Partners | Growth/Expansion | Minority | 000 0000 | 000000 0 | |
GVK BIO | PE-Backed Company | Minority | 000 0000 | 000000 0 | |
Lit Tele | Corporation | Minority | 000 0000 | 000000 0 |